Clovis Oncology Inc (CLVS) 68.79 $CLVS
Clovis Oncology to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 7:01AM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast, the Company's executive vice president and CFO, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, at 1:25 p.m. EST. The conference is being held at the Waldorf Astoria in New York City.
CLVS: 68.79 (+0.71)
Viscira(R) Delivers Record Business Results in 2014
PRWeb - Wed Feb 04, 2:20AM CST
Viscira, a leading provider of interactive, new-media communication solutions and software products for the life sciences industry, continued its stellar business performance in 2014. The company realized just over a 40% increase in gross revenue for FY 2014 as compared to FY 2013. Booked revenue grew by almost 50% over this same period.
CLVS: 68.79 (+0.71), BMY: 60.04 (+0.56)
InsiderInsights.com Daily Round Up 1/20/15: WIW, WIA, OPK, MLNK
InsiderInsights - at Seeking Alpha - Wed Jan 21, 7:39AM CST
NLSN: 45.59 (+2.02), TWMC: 3.67 (+0.12), QADA: 20.36 (+0.14), LNG: 74.48 (+0.90), DIS: 104.17 (+0.59), MLNK: 3.78 (+0.04), RM: 15.88 (+0.96), GOOG: 549.01 (+6.08), CI: 114.47 (-0.51), WIW: 11.29 (unch), SAR: 15.78 (+0.23), OPK: 13.80 (-0.28), BGT: 13.20 (+0.02), CLVS: 68.79 (+0.71), CDNA: 6.30 (-0.14), DYN: 28.39 (+0.01), SWN: 27.36 (+0.51), MA: 87.14 (-0.38), WIA: 11.49 (-0.03)
Clovis Oncology, Inc. (CLVS) in Focus: Stock Jumps 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 8:18AM CST
Clovis Oncology, Inc. (CLVS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
CLVS: 68.79 (+0.71), AFFX: 11.45 (+0.02)
Clovis Oncology to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 05, 5:30PM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco.
JPM: 59.67 (+0.10), CLVS: 68.79 (+0.71)
AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:48PM CST
AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian cancer.
AGN: 229.49 (+1.87), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 20, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
IMDZ: 25.34 (+1.20), ANY: 3.52 (+0.05), SNCR: 43.89 (+1.06), CLVS: 68.79 (+0.71), CYAN: 8.72 (+0.13), RTRX: 13.92 (+0.44), RAVN: 21.95 (+0.17), RMTI: 11.17 (+0.15), DWCH: 6.26 (-0.18)
Foundation Medicine's Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology's PARP inhibitor, Rucaparib
Business Wire - Wed Nov 19, 5:05PM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the presentation of new data from its ongoing collaboration with Clovis Oncology (NASDAQ: CLVS) to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine's novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.
FMI: 48.88 (+0.17), CLVS: 68.79 (+0.71)
Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients
Business Wire - Wed Nov 19, 5:01PM CST
--Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations
CLVS: 68.79 (+0.71)
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - Wed Nov 19, 10:41AM CST
CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20)
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - Wed Nov 19, 8:38AM CST
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20)
Clovis off premarket after report on CO-1686
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:21AM CST
CLVS: 68.79 (+0.71)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST
SGYP: 2.98 (unch), ANV: 0.97 (-0.03), VIPS: 21.80 (+0.36), CLVS: 68.79 (+0.71), SUNE: 21.45 (+0.30), SNSS: 2.28 (+0.01), CLF: 7.00 (+0.35), GSAT: 2.40 (+0.08), EJ: 7.44 (+0.01), OPLK: 24.23 (-0.03), LITB: 5.55 (-0.13)
Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
Business Wire - Tue Nov 18, 5:36PM CST
--Median PFS of 10.4 months in clinical dose group; data continue to mature
CLVS: 68.79 (+0.71)
Clovis teams up with Glaxo on combo cancer therapy
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:20AM CST
CLVS: 68.79 (+0.71), GSK: 47.94 (+1.99)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 38.47 (+0.27), DHX: 8.56 (unch), ACT: 285.37 (+3.71), OME: 11.03 (+0.01), CLVS: 68.79 (+0.71), AVB: 170.82 (-2.57), PF: 36.18 (-0.21), RMTI: 11.17 (+0.15), GLW: 25.00 (+0.14), FOLD: 8.36 (-0.11)
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Business Wire - Mon Nov 17, 4:00PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
CLVS: 68.79 (+0.71), GSK: 47.94 (+1.99)
Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Business Wire - Wed Nov 12, 4:28PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
CLVS: 68.79 (+0.71)
Clovis Oncology to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 7:01AM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast, the Company's executive vice president and CFO, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, at 1:25 p.m. EST. The conference is being held at the Waldorf Astoria in New York City.
CLVS: 68.79 (+0.71)
Viscira(R) Delivers Record Business Results in 2014
PRWeb - Wed Feb 04, 2:20AM CST
Viscira, a leading provider of interactive, new-media communication solutions and software products for the life sciences industry, continued its stellar business performance in 2014. The company realized just over a 40% increase in gross revenue for FY 2014 as compared to FY 2013. Booked revenue grew by almost 50% over this same period.
CLVS: 68.79 (+0.71), BMY: 60.04 (+0.56)
InsiderInsights.com Daily Round Up 1/20/15: WIW, WIA, OPK, MLNK
InsiderInsights - at Seeking Alpha - Wed Jan 21, 7:39AM CST
NLSN: 45.59 (+2.02), TWMC: 3.67 (+0.12), QADA: 20.36 (+0.14), LNG: 74.48 (+0.90), DIS: 104.17 (+0.59), MLNK: 3.78 (+0.04), RM: 15.88 (+0.96), GOOG: 549.01 (+6.08), CI: 114.47 (-0.51), WIW: 11.29 (unch), SAR: 15.78 (+0.23), OPK: 13.80 (-0.28), BGT: 13.20 (+0.02), CLVS: 68.79 (+0.71), CDNA: 6.30 (-0.14), DYN: 28.39 (+0.01), SWN: 27.36 (+0.51), MA: 87.14 (-0.38), WIA: 11.49 (-0.03)
Clovis Oncology, Inc. (CLVS) in Focus: Stock Jumps 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 8:18AM CST
Clovis Oncology, Inc. (CLVS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
CLVS: 68.79 (+0.71), AFFX: 11.45 (+0.02)
Clovis Oncology to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 05, 5:30PM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco.
JPM: 59.67 (+0.10), CLVS: 68.79 (+0.71)
AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:48PM CST
AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian cancer.
AGN: 229.49 (+1.87), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 20, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
IMDZ: 25.34 (+1.20), ANY: 3.52 (+0.05), SNCR: 43.89 (+1.06), CLVS: 68.79 (+0.71), CYAN: 8.72 (+0.13), RTRX: 13.92 (+0.44), RAVN: 21.95 (+0.17), RMTI: 11.17 (+0.15), DWCH: 6.26 (-0.18)
Foundation Medicine's Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology's PARP inhibitor, Rucaparib
Business Wire - Wed Nov 19, 5:05PM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the presentation of new data from its ongoing collaboration with Clovis Oncology (NASDAQ: CLVS) to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine's novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.
FMI: 48.88 (+0.17), CLVS: 68.79 (+0.71)
Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients
Business Wire - Wed Nov 19, 5:01PM CST
--Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations
CLVS: 68.79 (+0.71)
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - Wed Nov 19, 10:41AM CST
CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20)
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - Wed Nov 19, 8:38AM CST
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20)
Clovis off premarket after report on CO-1686
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:21AM CST
CLVS: 68.79 (+0.71)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST
SGYP: 2.98 (unch), ANV: 0.97 (-0.03), VIPS: 21.80 (+0.36), CLVS: 68.79 (+0.71), SUNE: 21.45 (+0.30), SNSS: 2.28 (+0.01), CLF: 7.00 (+0.35), GSAT: 2.40 (+0.08), EJ: 7.44 (+0.01), OPLK: 24.23 (-0.03), LITB: 5.55 (-0.13)
Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
Business Wire - Tue Nov 18, 5:36PM CST
--Median PFS of 10.4 months in clinical dose group; data continue to mature
CLVS: 68.79 (+0.71)
Clovis teams up with Glaxo on combo cancer therapy
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:20AM CST
CLVS: 68.79 (+0.71), GSK: 47.94 (+1.99)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 38.47 (+0.27), DHX: 8.56 (unch), ACT: 285.37 (+3.71), OME: 11.03 (+0.01), CLVS: 68.79 (+0.71), AVB: 170.82 (-2.57), PF: 36.18 (-0.21), RMTI: 11.17 (+0.15), GLW: 25.00 (+0.14), FOLD: 8.36 (-0.11)
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Business Wire - Mon Nov 17, 4:00PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
CLVS: 68.79 (+0.71), GSK: 47.94 (+1.99)
Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Business Wire - Wed Nov 12, 4:28PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
CLVS: 68.79 (+0.71)
